Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash from Financing Activities for 18 years, with the latest figure at -$1.2 billion in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 8.54% year-over-year to -$1.2 billion in Q2 2026; TTM through Jun 2026 was -$3.5 billion, a 11.59% increase from a year earlier, with the FY2025 full-year figure at -$3.7 billion, down 68.84% from the prior year.
• Cash from Financing Activities was -$1.2 billion for Q2 2026 at Regeneron Pharmaceuticals, down from -$802.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $64.7 million in Q1 2022, with the low at -$1.2 billion in Q2 2026.
• Average Cash from Financing Activities over 5 years is -$596.8 million, with a median of -$624.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities surged 117.66% in 2022, then plunged 2412.53% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$247.6 million in 2022, then plunged by 80.17% to -$446.1 million in 2023, then plunged by 154.54% to -$1.1 billion in 2024, then jumped by 31.3% to -$780.1 million in 2025, then sank by 56.98% to -$1.2 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$1.2 billion (Q2 2026), -$802.2 million (Q1 2026), and -$780.1 million (Q4 2025), per Business Quant data.